Liu Qi, Chen Zhiqiang, Terry Toya, McNatt Janice M, Willerson James T, Zoldhelyi Pierre
Wafic Said Stem Cell and Gene Therapy Research Laboratory, Texas Heart Institute at St Luke's Episcopal Hospital, Houston, Texas.
Vasc Endovascular Surg. 2009 Oct-Nov;43(5):433-43. doi: 10.1177/1538574409335158. Epub 2009 Jul 23.
Bone marrow cell therapy promotes angiogenesis, but the cellular fate of bone marrow cells (BMCs) in the absence of immunosuppressant interventions is unclear. We created a model of severe hind limb ischemia to address whether BMCs form new blood vessels or differentiate into other tissues.
After ligating the common femoral artery in ApoE knockout mice, we injected either phosphate buffered saline (PBS) or 5 x 10(7) adult unfractionated BMCs obtained from green fluorescent protein-positive mice. Laser Doppler imaging of the ischemic limbs revealed that intra-arterial BMCs significantly increased blood flow recovery in ischemic limbs beginning 21 days after surgery and peaking at 27 days (61.8% +/- 15% vs. 41.9% +/- 13.9%, respectively, for BMCs and PBS, P < .05). The BMCs differentiated into small blood vessels, skeletal myofibers, and supporting membranes, and these changes were associated with increased serum levels of vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), transforming growth factor beta (TGFbeta), interleukin 4 (IL-4), and tumor necrosis factor alpha (TNF-alpha).
Adult BMCs injected into ischemic limbs without immunosuppressant therapy differentiated into blood vessels and skeletal myofibers, and this was associated with accelerated blood flow restoration and increased serum levels of VEGF, FGF-2, TGF-beta, IL-4, and TNF-alpha. Skeletal muscle formation may provide benefits beyond angiogenesis to patients with chronic peripheral arterial disease or to patients with low cardiac output states who also suffer from skeletal muscle atrophy.
骨髓细胞疗法可促进血管生成,但在无免疫抑制干预情况下骨髓细胞(BMCs)的细胞命运尚不清楚。我们建立了严重后肢缺血模型,以探讨BMCs是否形成新血管或分化为其他组织。
在载脂蛋白E基因敲除小鼠中结扎股总动脉后,我们注射了磷酸盐缓冲盐水(PBS)或从绿色荧光蛋白阳性小鼠获得的5×10⁷个未分级的成年BMCs。对缺血肢体进行激光多普勒成像显示,动脉内注射BMCs可使缺血肢体的血流恢复显著增加,从术后21天开始,在27天达到峰值(BMCs组和PBS组分别为61.8%±15%和41.9%±13.9%,P<0.05)。BMCs分化为小血管、骨骼肌纤维和支持膜,这些变化与血清血管内皮生长因子(VEGF)、成纤维细胞生长因子2(FGF-2)、转化生长因子β(TGFβ)、白细胞介素4(IL-4)和肿瘤坏死因子α(TNF-α)水平升高有关。
在无免疫抑制治疗的情况下,将成年BMCs注入缺血肢体可分化为血管和骨骼肌纤维,这与血流恢复加速以及血清VEGF、FGF-2、TGF-β、IL-4和TNF-α水平升高有关。骨骼肌形成可能为慢性外周动脉疾病患者或伴有骨骼肌萎缩的低心输出量状态患者带来超出血管生成的益处。